Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

Single Molecule with Dual Mechanism May Offer Novel Approach to Blood

Pressure Management

NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension. PS433540 is being developed as a potential treatment for both hypertension and diabetic nephropathy and is a novel blood pressure product candidate that possesses two validated mechanisms of action in a single molecule. The data will be presented today at the Recent and Late Breaking Clinical Trials Session at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in New Orleans.

The Phase 2a study met its primary endpoint by showing a statistically significant reduction in mean 24-hour systolic ambulatory blood pressure over placebo. The study also showed statistically significant improvements over placebo in mean 24-hour diastolic ambulatory blood pressure as well as seated blood pressure. In this double-blind, placebo-controlled study, patients treated with 200 mg of PS433540 once daily experienced a 12/9mmHg drop in mean 24-hour systolic and diastolic blood pressure and those treated with 500 mg experienced a 15/10mmHg drop in mean 24-hour systolic and diastolic blood pressure. These reductions were highly statistically significant vs. placebo (P<0.001). Mean seated office systolic and diastolic blood pressure, the typical blood pressure measure, was also evaluated, with observed blood pressure drops of 17/11mmHg with the 200 mg dose and 17/10mmHg with the 500 mg dose (P<0.001 vs. placebo).

Once-daily treatment with 200 or 500 mg of PS433540 was well tolerated. Most of the adverse events reported were mild o
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...5/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ...ebloodanalysissystems,announcedtodaythatClintSever...the21stAnnualPiperJaffrayHealthCareConferenceonWed...lbeheldattheNewYorkPalaceHotelinNewYorkCity. ,,...dmarketsportablebloodanalysissystemsforuseinanyvet...
(Date:11/25/2009)...RNewswire/--AccordingtoMillenniumResearchGroup(MRG...ligence,thenearly$3billionUSmarketfortraumafixatio...eyearsdespitetherecenteconomicslowdown.MRG,s USMar...etwillremainhighlydynamicoverthenextfiveyears,with...lyunderservedsegmentsofthetraumafixationmarket,fue...
(Date:11/25/2009).../PRNewswire/--CempraPharmaceuticalsInc.todayannoun...tiveofficer,willpresentatthePiperJaffray21stAnnual...tTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernandeswi...ticclinicalprogramsforthetreatmentofdrug-resistant...uticals ,, Foundedin2006,CempraPharmaceuticals...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Five Questions About Eczema 53569 1Five Questions About Eczema 53569 2Five Questions About Eczema 53569 3Five Questions About Eczema 53569 4Five Questions About Eczema 53569 5Validation 26 Compliance Institute LLC to Provide Medical Device Regulatory Training for the University of Michigans Medical Innovation Center 53568 1Validation 26 Compliance Institute LLC to Provide Medical Device Regulatory Training for the University of Michigans Medical Innovation Center 53568 2Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 1Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 2Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 3Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 4Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 5Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 6Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 7
(Date:11/27/2009)..., NEUILLY-SUR-SEINE,France,Nov.27/PRNewswire/...alcyclingteamdedicatedtoethicalsportinganddevelopi...aythatitwillbecomeTeamGarmin-Transitionswiththeadd...ansitionsOpticalistheworld,sleadingmanufacturerofa...technologyinthewidestselectionofspectaclelensessuc...
(Date:11/27/2009)..., SEATTLE,Nov.27/PRNewswire/-- Allrecipes.com...givingtrafficnumbers,withmorethan2.8millionvisitor...whatwasservedonthebiggestfoodholidayoftheyear.Thea...esperserving,a5percentincreasefromlastyear,sfeast....etheshowasthemostpopularThanksgivingrecipe,acontra...
(Date:11/26/2009)..., NEWYORK,Nov.27/PRNewswire/--Withcoldandflus...racticestocontrolthespreadofinfectionsandavoidilln...veshealthy,buttoavoidtransmittingillnessifwe,resic...n-control),nursingdirectorforinfectioncontrolandoc...Manhattan. ,, HospitalforSpecialSurgeryhasoneof...
(Date:11/26/2009)...ans get a bigger thrill when on an emotional rolle... 26 (HealthDay News) -- Call it the fear factor me...ests that spectators -- especially those who root ...ction if it,s a closely contested match and victor...en despair. , Chew on that this Thanksgiving we...
(Date:11/26/2009)... Ennis & Ennis, P.A. i...ons for users of Yaz and Yasmin birth control pill...Pulmonary Embolism, Stroke, Heart Attack or other ...moved. Women can call toll free at 1-800-856-6405 ...nnislaw.com and fill out an online case evaluatio...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
...y shows Beer and liquor significantly increase the... the consumption of wine did not // appear to be a...igher in men who drank more than 50 grams of alcoh...When investigators analyzed the type of beverages,...
...about 400,000 Americans undergo balloon angioplast...teries become blocked again.// Now, a cancer drug ...Bailey can relax today, knowing he's doing everyth...e kind of chest pain. He says, "It was a grabbing,...
...s are now finding new ways to deliver gene therapy...e using lipids, oily molecules that can form a pro...as a virus. The lipids protect the DNA and help it... the promise of curing diseases such as diabetes, ...
... famine may be linked to an increased risk of brea... new study. // Researchers found women who experie...uring the 1944-1945 Dutch famine were more likely ...ed in the Dutch breast cancer screening program be...
...ing a treatment plan for Leukemia , doctors rely o...s likely to be, // including how the cancer cells ...sease history. However, for some patients, those i...overed 133 genes that point to the most dangerous ...
... studies found to offer good news for older adults...rams can reduce depression // in the elderly. Rese...ut half of the participants suffered from major de...Results of the study show seniors who received the...
Other Medicine News:
Midas Rex Legend Platinum Drill System
Relocatable Non-Invasive Frame (for fractionation)
Leksell Stereotactic System
FastSystem® AF400 Anterior Lumbar Retractor System
Medicine Products: